Cibisatamab
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research[1].
Product Specifications
CAS Number
1855925-27-7
UNSPSC
12352203
Target
CD3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cibisatamab.html
Purity
99.75
Solubility
H2O
Smiles
[Cibisatamab]
Molecular Weight
(171 kDa)
References & Citations
[1]Reyes Gonzalez-Exposito, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019 Apr 15;7 (1) :101.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400960-100 1x 100 µL
MUC1 / EMA / CD227 (Epithelial Marker) (rMUC1/960), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
